You are viewing Asia Pacific

Supporting Young Eyes and Minds with FloraGLO® Lutein

Posted August 29, 2024

At Kemin, we are dedicated to advancing the science behind lutein, particularly through our flagship ingredient, FloraGLO® lutein. Our commitment to promoting children's health, especially regarding eye health and cognitive development, drives our research and product development efforts. Compelled by curiosity, we continuously explore new ways to enhance the well-being of children.

The Role of Lutein in Children's Health

Kemin introduced FloraGLO lutein to the market 27 years ago, and it is now backed by over 116 clinical studies.1 We are currently focusing on the children's health sector, recognizing the importance of lutein in this age group.

Children today are exposed to significant amounts of blue light from screens, making lutein's protective properties for the retina—an extension of the brain—crucial.

Distinguishing Kemin’s Lutein Offerings

Kemin’s carotenoid portfolio, with FloraGLO lutein at its core, stands out due to its safety, quality, and efficacy. FloraGLO lutein is the only lutein source that is Generally Recognized As Safe (GRAS)3 for use in infant and pre-term infant formulas. This approval underscores the safety and reliability of our ingredient, providing parents with peace of mind.

Formulating for Children's Products

Creating formulations specifically for children involves unique challenges. Products must be palatable, easy to consume daily, and safe. FloraGLO lutein meets these requirements perfectly. Its versatile flavor profile makes it suitable for various formats, including gummies and beverages, ensuring that children enjoy taking it regularly.

Collaborating with Supplement Manufacturers

At Kemin, we view our relationships with supplement manufacturers as full partnerships. From initial discussions to product development and ongoing support, we work closely with our partners to create successful products. Our Customer Lab Service Group assists with formulation, flavor profiles, and resolving any specific challenges related to our ingredients.

Conclusion

Compelled by curiosity, Kemin continues to lead in the development of innovative solutions for health and wellness. To learn more about FloraGLO lutein and how Kemin can support your formulations to enhance children's health and wellness, please visit Kemin.com.


Resources

Enhancing Eye Health

Shining a New Light on Skin Health

Supporting Eye & Brain Health

FloraGLO® Lutein: So Much More Than An "Eye Vitamin"


Subscribe to our Blog

 

 

These statements have not been evaluated by the US Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

The information on this webpage is a business-to-business information and not intended for the final consumer. Certain statements may not be applicable in all geographical regions. Product labeling and associated claims differs based upon government requirements and country or region specific information should also be considered when labeling or advertising to final consumers.

This web page and its associated brochures and other documents do not constitute or provide scientific or medical advice, diagnosis, or treatment and are distributed without warranty of any kind, either expressly or implied. This web page, its title or contents and associated brochures and other documents do not in any way make recommendations for health or marketing claims by the reader. Country and region specific regulations should be considered in this regard. Each claim or statement about the effectiveness of Kemin products and/or each claim or statement comparing the effectiveness of Kemin products to the effectiveness of other products is expressly limited to the United States, unless otherwise disclosed on the Kemin websites.

References:

  1. PubMed, 2018.
  2. Roberts, Richard. “Methods of Treating Ocular Disorders.” Kemin Industries, Inc., assignee. Patent US9226940 B2. Jan. 2016. Kemin's patent covers three conditions for all ages; presbyopia, hyperopia, and astigmatism.
  3. U.S. Food & Drug Administration, 2004. GRAS Notice Inventory, GRN No. 140, 221 and 390.